IL290247A - Cancer treatment by a combination of an antibody against lgr5 and egfr and an inhibitor of topoisomerase i - Google Patents

Cancer treatment by a combination of an antibody against lgr5 and egfr and an inhibitor of topoisomerase i

Info

Publication number
IL290247A
IL290247A IL290247A IL29024722A IL290247A IL 290247 A IL290247 A IL 290247A IL 290247 A IL290247 A IL 290247A IL 29024722 A IL29024722 A IL 29024722A IL 290247 A IL290247 A IL 290247A
Authority
IL
Israel
Prior art keywords
topoisomerase
egfr
antibody
cancer
inhibitor
Prior art date
Application number
IL290247A
Other languages
English (en)
Hebrew (he)
Inventor
Throsby Mark
Isaac Wasserman Ernesto
Original Assignee
Merus Nv
Throsby Mark
Isaac Wasserman Ernesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv, Throsby Mark, Isaac Wasserman Ernesto filed Critical Merus Nv
Publication of IL290247A publication Critical patent/IL290247A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL290247A 2019-08-19 2022-01-30 Cancer treatment by a combination of an antibody against lgr5 and egfr and an inhibitor of topoisomerase i IL290247A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19192327 2019-08-19
PCT/NL2020/050517 WO2021034194A2 (en) 2019-08-19 2020-08-19 Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor.

Publications (1)

Publication Number Publication Date
IL290247A true IL290247A (en) 2022-03-01

Family

ID=67659296

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290247A IL290247A (en) 2019-08-19 2022-01-30 Cancer treatment by a combination of an antibody against lgr5 and egfr and an inhibitor of topoisomerase i

Country Status (12)

Country Link
US (1) US20230084382A1 (enExample)
EP (1) EP4017879A2 (enExample)
JP (2) JP7536085B2 (enExample)
KR (1) KR20220048015A (enExample)
CN (2) CN114555115A (enExample)
AU (1) AU2020331879C1 (enExample)
BR (1) BR112022003143A2 (enExample)
CA (1) CA3151641A1 (enExample)
IL (1) IL290247A (enExample)
MX (1) MX2022002096A (enExample)
PH (1) PH12022550306A1 (enExample)
WO (1) WO2021034194A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240207457A1 (en) * 2021-05-11 2024-06-27 The Catholic University Of Korea Industry-Academic Cooperation Foundation Cancer-specific polypeptide and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
EP1286671B1 (en) * 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
KR20180138205A (ko) * 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여

Also Published As

Publication number Publication date
WO2021034194A2 (en) 2021-02-25
JP7536085B2 (ja) 2024-08-19
AU2020331879A1 (en) 2022-02-24
WO2021034194A3 (en) 2021-04-01
AU2020331879B2 (en) 2025-07-17
PH12022550306A1 (en) 2023-07-31
US20230084382A1 (en) 2023-03-16
CA3151641A1 (en) 2021-02-25
JP2024075676A (ja) 2024-06-04
JP2022545457A (ja) 2022-10-27
KR20220048015A (ko) 2022-04-19
CN116333154A (zh) 2023-06-27
EP4017879A2 (en) 2022-06-29
CN114555115A (zh) 2022-05-27
AU2020331879C1 (en) 2025-11-27
NZ784830A (en) 2025-09-26
BR112022003143A2 (pt) 2022-05-17
MX2022002096A (es) 2022-03-17

Similar Documents

Publication Publication Date Title
IL288522A (en) Inhibitor of egfr for cancer treatment
IL313807A (en) Claudin 18 antibodies and methods for cancer treatment
IL278772A (en) Antibodies against 40-OX and methods of use
HUE061842T2 (hu) A rák kezelésének módszerei anti-PD-1 antitestekkel
IL286473A (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
EP3313433A4 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
IL245219B (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
EP3270966A4 (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
IL275940A (en) Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
EP4007640A4 (en) CANCER COMBINATION THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPY AGENTS
IL266521A (en) A combination of a brd4 inhibitor and an antiplatelet for cancer treatment
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL282646A (en) Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
IL268000A (en) Cancer treatment with semphorin-4d antibody in combination with an epigenetic modulator factor
IL279548A (en) Methods for treating lung cancer with a PD-1 spindle-binding antagonist, a platinum agent, and a topoisomerase II inhibitor
IL259416A (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
SG11202009986QA (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HUE071862T2 (hu) L718 és/vagy L792 mutáns, kezelésre rezisztens EGFR inhibitor rák kezelésében történõ alkalmazásra
EP3735472A4 (en) KITS AND METHODS FOR DETECTING CANCER MUTATIONS
EP3854886A4 (en) METHODS AND KITS FOR DETERMINING CANCER RISK
HK40067633A (en) Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor
EP3812461A4 (en) STOMACH CANCER BIOMARKER AND ITS USE
EP4061844A4 (en) METHODS OF TREATING CANCER WITH ANTI-OX40 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY AGENTS
IL284320A (en) tim-3 antibodies and combinations with other checkpoint inhibitors for cancer therapy